08:30~08:55 | »çÀüÁ¢¼Ó½Ã°£ | |
08:55~09:00 | Opening Address | ´ëÇÑôÃßÅëÁõÇÐȸÀå ÀÌÆòº¹ |
Session I | Developing clinical guidelines in real- world practice | ÁÂÀå: ¼¿ï¾Æ»êº´¿ø ½ÅÁø¿ì |
09:00-09:25 | Guideline development in pain medicine | Steven P. Cohen (Johns Hopkins Univ., USA) |
09:25-09:50 | Clinical guidelines on facet blocks and RF ablation: Extrapolation from the lumbar to cervical Spine | Steven P. Cohen (Johns Hopkins Univ., USA) |
09:50~10:00 | Coffee Break | ¡¡ |
Session II | Updates in the modality of spinal pain | ÁÂÀå: ¾ç»êºÎ»ê´ëº´¿ø ±è°æÈÆ ÇѾç´ë±¸¸®º´¿ø ½ÉÀçÇ× |
10:00-10:25 | New medication -NSAIDs updates -Mirogabalin -Capsaicin, LidocaineÀÇ È°¿ë |
¿ø±¤´ëº´¿ø ±è¿¬µ¿ |
10:25-10:50 | New injection drug for spinal intervention -Other than steroids |
ÇØ¿î´ë¹éº´¿ø ÀÌ»óÀº |
10:50-11:15 | New approach to the epidural space -Controlateral oblique approach for cervical epidural injection -Other approaches for thoracic and lumbar level |
ºÐ´ç¼¿ï´ëº´¿ø ÃÖÀºÁÖ |
11:15-11:25 | Q & A | ¡¡ |
11:25-11:35 | Coffee break | ¡¡ |
Session III | Address to the new normal | ÁÂÀå: ºÐ´ç¼¿ï´ëº´¿ø ÀÌÆòº¹ |
11:35-12:25 | µ¥ÀÌÅÍ ½ÃÀåÀÇ ÁøÈ¿Í ÀΰøÁö´ÉÀÇ ºÎ»ó, ±×¸®°í Tesla | ±èÁؼº (¸Þ¸®Ã÷Áõ±Ç ¾Ö³Î¸®½ºÆ®) |
12:25-13:25 | Lunch | ¡¡ |
Session IV | Video demonstration of ultrasonography for pain medicine | ÁÂÀå: ÀÌ»óö¸¶ÃëÅëÁõÀÇÇаúÀÇ¿ø ÀÌ»óö °í´ë±¸·Îº´¿ø ÃÖ»ó½Ä |
13:25-14:00 | USG guided intervention for thoracic pain -ÈäÃߺΠÅëÁõ Ä¡·á¸¦ À§ÇÑ ÃÊÀ½ÆÄ ½Ã¼úÀÇ È°¿ë -Áغñ °úÁ¤ ºÎÅÍ ½Ã¼úÀÇ ½ÇÁ¦ |
¼¿ï¾Æ»êº´¿ø ±èµÎȯ |
14:00-14:35 | USG guided intervention for cervical pain -°æÃߺΠÅëÁõ Ä¡·á¸¦ À§ÇÑ ÃÊÀ½ÆÄ ½Ã¼úÀÇ È°¿ë -Áغñ °úÁ¤ ºÎÅÍ ½Ã¼úÀÇ ½ÇÁ¦ |
¼¼ºê¶õ½ºº´¿ø ¹Ú»óÁØ |
14:35-14:45 | Q & A | ¡¡ |
14:45-14:55 | Coffee break | ¡¡ |
Session V | Spinal pain in the elderly: What we have to address | ÁÂÀå: ¿©Àǵµ¼º¸ðº´¿ø ¼ºÃáÈ£ ¹ÚÇмö¸¶ÃëÅëÁõÀÇÇаúÀÇ¿ø ¹ÚÇмö |
14:55-15:15 | Collagen and exercise in sarcopenia | ÀºÆò¼º¸ðº´¿ø ¹®È£½Ä |
15:15-15:35 | Dangers of polypharmacy in the elderly with spinal pain | »ï¼º¼¿ïº´¿ø ÀÌÁø¿µ |
15:35-15:55 | Spinal pain in patients with Parkinson's and movement disorder | ÇѸ²´ë¼º½Éº´¿ø ½Å°æ°ú ±è¿µÀº |
15:55-16:05 | Q & A | ¡¡ |
16:05-16:15 | Coffee Break | ¡¡ |
Session VI | Case presentation: sharing your ideas | ÁÂÀå: ±è¿ëö¸¶ÃëÅëÁõÀÇÇаúÀÇ¿ø ±è¿ëö °í½Å´ëº´¿ø ±èµÎ½Ä |
16:15-16:30 | Unspecified back pain | ÄÛ¸¶ÃëÅëÁõÀÇÇаúÀÇ¿ø ±èȯÈñ |
16:30-16:45 | Thoracic disc herniation : 2 cases | ÀüºÏ´ëº´¿ø µÎ¾Æ¶÷ |
16:45-17:00 | Adverse reactions after erector spinae plane blocks for pain control : 2 cases | ÃæºÏ´ëº´¿ø ±èÇöÅ |
17:00-17:10 | Q & A | |
17:10-17:15 | Closing Remark | ´ëÇÑôÃßÅëÁõÇÐȸÀå ÀÌÆòº¹ |
08:30-09:00 | Registration | |
09:00-09:10 | Opening address | ±èµ¿ÀÍ (´ëÇÑÇ÷°ü¿Ü°úÇÐȸ ȸÀå) |
09:10-10:40 | Free paper session 1 | ÁÂÀå: À±»ó¼· (°¡Å縯ÀÇ´ë) ¹Ú»óÁØ (¿ï»êÀÇ´ë) |
09:10-09:19 | Osteopontin is a key regulator of vascular smooth muscle cell proliferation in the outflow of AVF | °í´ë½Ä (°¡ÃµÀÇ´ë) |
09:19-09:28 | Expression of miRNAs Targeting ABCA1 Among Patients with Significant Carotid Artery Stenosis | Á¤¼±Á¤ (¿ï»êÀÇ´ë) |
09:28-09:37 | Electrospun graft from PCL/ decellularized ECM hybrid polymer for small-caliber vascular application | ÇѾƶ÷ (¼¿ïÀÇ´ë) |
09:37-09:46 | Prospective observational study of treatment in symptomatic C1 patients with saphenous vein reflux | Á¶¾Æ¶ó (¼¿ïÀÇ´ë) |
09:46-09:55 | Lung cancer as a risk factor for abdominal aortic aneurysm | ±ÇÁؼº (ÂüÇÏÁö¿Ü°ú) |
09:55-10:04 | The impact of introducing a hybrid operating room on the hybrid vascular procedure. | ½Å¿µÈç (¼¿ïÀÇ´ë) |
10:04-10:13 | Characteristics of Korean patients with venous thromboembolism compared to Western population | ±èÁö¼± (Bayer Korea) |
10:13-10:22 | Clinical outcomes of non-thermal ablation, thermal ablation, & surgical stripping for varicose vein | Á¶¼º½Å (°æÈñÀÇ´ë) |
10:22-10:31 | Comparison between RFA for vein removal and CHIVA strategy to preserve veins | À±»óö (¼øõÇâÀÇ´ë) |
10:31-10:40 | Outcomes of Surgically Treated Arteriovenous Fistula Aneurysm in Patients on Regular Hemodialysis | Á¶¼º½Å (°æÈñÀÇ´ë) |
10:40-11:00 | Coffee Break | |
11:00-12:00 | Symposium 1 - What¡¯s new in the vascular world | ÁÂÀå: Á¶ÁøÇö (°æÈñÀÇ´ë) °Áø¸ð (°¡ÃµÀÇ´ë) |
11:00-11:15 | K-DOQI guideline updates: What is the life-plan for ESRD patients? | ±èÇâ°æ (¿ï»êÀÇ´ë) |
11:15-11:30 | Is IVUS highly recommended for PAD intervention? | TBD |
11:30-11:45 | Recent updates in NOAC - new indications | ÇѾƶ÷ (¼¿ïÀÇ´ë) |
11:45-12:00 | Changes in visceral aneurysm management guidelines | ȲÁ¤±â (°¡Å縯ÀÇ´ë) |
12:00-12:30 | ȸÀå°¿¬ | ÁÂÀå: ÀåÀÌÂù (ÃæºÏÀÇ´ë) |
12:00-12:30 | Ç÷°ü¿Ü°ú ÀÇ»çÀÇ ±æ | ±èµ¿ÀÍ (¼º±Õ°üÀÇ´ë) |
12:30-13:30 | Luncheon | ÁÂÀå: ±èÇü±â (°æºÏÀÇ´ë) |
12:30-13:00 | Heli-FX Endoanchor 5Yrs Registry | I-Hui Wu (National Taiwan University Hospital, Taiwan) |
13:00-13:30 | ENGAGE 8Yrs | Vincent Riambau (Teknon Medical Center, Spain) |
13:30-15:00 | Free Paper Session 2 | ÁÂÀå: Á¶¿ëÇÊ (¿ï»êÀÇ´ë) ¾ÈÇüÁØ (°æÈñÀÇ´ë) |
13:30-13:39 | Late open surgical conversion after endovascular aortic aneurysm repair: A 20-year experience | ¹Ú¾çÁø (¼º±Õ°üÀÇ´ë) |
13:39-13:48 | The Uncomfortable Truth on Outcomes Related to Ruptured Abdominal Aortic Aneurysm in Korea | Á¶Àº¾Æ (¼¿ïÀÇ´ë)) |
13:48-13:57 | Comparison of treatment outcomes based on risk stratification in carotid revascularization | ¹ÚÁرâ (¼º±Õ°üÀÇ´ë) |
13:57-14:06 | Duplex ultrasound findings and clinical outcomes of carotid restenosis after carotid endarterectomy | À念Áø (¿ï»êÀÇ´ë) |
14:06-14:15 | Clinical outcomes of hypogastric artery interruption during endovascular aneurysm repair | ±èÇöÁÖ (°æºÏÀÇ´ë) |
14:15-14:24 | The Feasibility of Fenestrated EVAR from Korean single institution data base | Çö»óÈ£ (¼¿ï¼º¸ðº´¿ø) |
14:24-14:33 | Clinical characteristics affecting the treatment outcome of pseudoaneurysms after femoral access | Á¤ÇüÀº (ÀüºÏÀÇ´ë) |
14:33-14:42 | Can prosthetic grafts be an alternative option for below knee bypass? | ±è¿µÇý (°æºÏÀÇ´ë) |
14:42-14:51 | Outcomes of CEA compared between primary and patch closure; using propensity score matching analysis | ±è¹Î±Ô (¼º±Õ°úÀÇ´ë) |
14:51-15:00 | Effect of angioplasty on sarcopenia in PAOD patients | ±èµ¿Çö (ºÎ»êÀÇ´ë) |
15:00-16:00 | Symposium 2 - Challenges in AAA treatment | ÁÂÀå: ¹Ú±âÇõ (´ë±¸°¡Å縯ÀÇ´ë) ¹Ú¾çÁø (¼º±Õ°üÀÇ´ë) |
15:00-15:15 | Has EVAR been satisfactory? Open repair is to be revisited for hostile anatomy | ¾È»óÇö (¼¿ïÀÇ´ë) |
15:15-15:30 | PAU or IMH as new indications for endovascular treatment | Á¤ÇõÀç (ºÎ»êÀÇ´ë) |
15:30-15:45 | T-branch/P-branch for TAAA | Bijan Modarai (King¡¯s College London, United Kingdom) |
15:45-16:00 | Does EndoAnchor help widen the indications for EVAR with hostile neck? | ¹ÚÀÇÁØ (°è¸íÀÇ´ë) |
16:00-16:20 | Coffee Break | |
16:20-17:20 | Poster Presentation | ÁÂÀå: Á¤Àθñ (¼¿ïÀÇ´ë) ¾È¹®»ó (Ãæ³²ÀÇ´ë) |
16:20-16:27 | PostCyanoacrylate Allergic Reaction(PoCAR) after cyanoacrylate closure operation for varicose vein | ±è´ëÁß (ºÎ»êÀÇ´ë) |
16:27-16:34 | Complications and Mid-term Results after Isolated Endarterectomy of the Femoral Bifurcation | ¹Ú¼öÇö (°æºÏÀÇ´ë) |
16:34-16:41 | Risk factor of iliac artery rupture during aortoiliac artery stenting | À̱¤Áø (°æÈñÀÇ´ë) |
16:41-16:48 | Do more abdominal aortic aneurysm surgeries result in fewer postoperative complications? | ¹ÚÁ¦Çü (ºÎ»êÀÇ´ë) |
16:48-16:55 | Femoral endarterectomy with combined infrainguinal revascularization in multi-level arterial disease | ¹Ú¼öÇö (°æºÏÀÇ´ë) |
16:55-17:02 | À̹ÌÁö ±â¹Ý µö·¯´×À» È°¿ëÇÑ Ç¥Àç´ëÅðµ¿¸Æ Áúȯ ºÐ·ù | ÀÌ¿ä¼Á (¼¿ï¼º¸ðº´¿ø) |
17:02-17:09 | Prevalence and characteristics of superior mesenteric artery abnormalities by reviewing CT scan | À¯±Çö (ÃæºÏÀÇ´ë) |
17:09-17:13 | ¹ß »óó¸¦ µ¿¹ÝÇÑ ÁßÁõÇÏÁöÇãÇ÷ ȯÀÚ¿¡¼ TcPO2¸¦ ÀÌ¿ëÇÑ ÀÓ»ó°æÇè | ¿ì¿µÁ¦ (°Åⱺº¸°Ç¼Ò) |
17:13-17:20 | Clinical events analysis of venoactive drugs using the big data from the National Health Insurance | Á¶ÁøÇö (°æÈñÀÇ´ë) |
17:20-17:50 | ¿¬±¸ÀåÇÐ±Ý º¸°í | ÁÂÀå: Çã½Â (°æºÏÀÇ´ë) |
17:20-17:35 | 2019³â ÀÌ¿ë°¢ ¿¬±¸ÀåÇÐ±Ý (±âÃʺι®) ¼öÇýº¸°í | ¾ÈÇüÁØ (°æÈñÀÇ´ë) |
17:35-17:50 | 2019³â ÀÌ¿ë°¢ ¿¬±¸ÀåÇÐ±Ý (ÀÓ»óºÎ¹®) ¼öÇýº¸°í | Á¶ÁøÇö (°æÈñÀÇ´ë) |
17:50-18:00 | Award and Closing remarks | ±èµ¿ÀÍ (´ëÇÑÇ÷°ü¿Ü°úÇÐȸ ȸÀå) |
* ¸ðµç Âü¼®ÀÚ Ã¼¿Â ÃøÁ¤ ¿¹Á¤ * ¸¶½ºÅ© ¹ÌÂø¿ëÀÚ ÃâÀÔ ºÒ°¡